ASLAN reports interim data from atopic dermatitis drug trial
Singapore-based biopharmaceutical company ASLAN Pharmaceuticals has announced positive interim data from its Phase II TREK-DX study of eblasakimab, a drug…
Singapore-based biopharmaceutical company ASLAN Pharmaceuticals has announced positive interim data from its Phase II TREK-DX study of eblasakimab, a drug…
The epidemiology of atopic dermatitis (AD) is heterogeneous across countries and age groups. Traditionally, AD in South Korea has always…
This week on Pipeline Moves, we kick off by looking at a Phase III trial completion of Pfizer’s influenza vaccine…
ARS Pharmaceuticals expects to launch neffy (epinephrine nasal spray) in H2 2024, for which the company plans to submit a…
Previously in the literature, an association between those with vitiligo and an increased risk of developing osteoporosis has been speculated.…
Aquestive Therapeutics has revealed topline data from the Phase III pharmacokinetic (PK) study of its anaphylactic drug, Anaphylm (epinephrine) sublingual…
Sanofi has announced encouraging findings from the second part of a study with the OX40 antibody amlitelimab, which showed sustained…
Eli Lilly has released results from the Phase III Admirable trial of its monoclonal antibody, lebrikizumab, in patients with darker…
Johnson & Johnson (J&J) has reported initial findings from the Phase IIb FRONTIER 2 clinical trial, where JNJ-2113 offered high…
Maryland-based Alphyn Biologics announced that the second cohort in its Phase IIa trial evaluating zabalafin hydrogel (AB-101a) in AD and…